Confidence interval criteria for assessment of dose proportionality

Pharmaceutical Research

Volumn 17, Issue 10, 2000, Pages 1278-1283

  Smith, B P ^a   Vandenhende, F R ^b   DeSante, K A ^a,c   Farid, N A ^a   Welch, P A ^a,c   Callaghan, J T ^a,c   Forgue, S T ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Eli Lilly Benelux   (Belgium)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Bioequivalence; Dose proportionality; Mixed effects model; Pharmacokinetics; Power model

Indexed keywords

DRUG;

ARTICLE; BIOEQUIVALENCE; DOSE RESPONSE; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0033634992     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026451721686     Document Type: Article

References (14)

1. Modeling pharmacokinetic dose-proportionality data
2. A stepwise approach for analyzing dose proportionality studies
3. Dose-response in pharmacokinetics
4. Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacoinetics UK joint working party
5. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses
6. 1) in healthy volunteers following intravenous infusion
7. Pharmacokinetics of Testosterone in hypogonadal men after transdermal delivery: Influence of dose
8. Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects
9. Introduction of a composite parameter to the pharmacokinetics of Venalfaxine and its active O-desmethyl metabolite
10. Properties of the Michaelis-Menton equation and its integrated form which are useful in pharmacokinetics
11. Area-dose relationships in nonlinear models
12. Influence of dose range on degree of nonlinearity detected in dose-proportionality studies for drugs with saturable elimination: Single-dose and steady-state studies